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ABSTRACT 
Migraine and major depressive disorder (MDD) are common brain disorders that 
frequently co-occur. Despite epidemiological evidence that migraine and MDD share a 
genetic basis, their overlap at the molecular genetic level has not been thoroughly 
investigated. Using single nucleotide polymorphism (SNP) and gene-based analysis of 
genome-wide association study (GWAS) genotype data, we found significant genetic 
overlap across the two disorders. LD Score regression revealed a significant SNP-based 
heritability for both migraine (h2 = 12%) and MDD (h2 = 19%), and a significant cross-
disorder genetic correlation (rG = 0.25; P = 0.04). Meta-analysis of results for 8,045,569 
SNPs from a migraine GWAS (comprising 30,465 migraine cases and 143,147 control 
samples) and the top 10,000 SNPs from a MDD GWAS (comprising 75,607 MDD cases 
and 231,747 healthy controls), implicated three SNPs (rs146377178, rs672931, and 
rs11858956) with novel genome-wide significant association (PSNP ≤ 5 × 10-8) to migraine 
and MDD. Moreover, gene-based association analyses revealed significant enrichment of 
genes nominally associated (Pgene-based ≤ 0.05) with both migraine and MDD (Pbinomial-test 
= 0.001). Combining results across migraine and MDD, two genes, ANKDD1B and 
KCNK5, produced Fisher’s combined gene-based P values that surpassed the genome-
wide significance threshold (PFisher’s-combined ≤ 3.6 × 10-6). Pathway analysis of genes with 
PFisher’s-combined ≤ 1 × 10-3 suggested several pathways, foremost neural-related pathways 
of signalling and ion channel regulation, to be involved in migraine and MDD etiology. 
In conclusion, our study provides strong molecular genetic support for shared genetically 
determined biological mechanisms underlying migraine and MDD. 
Keywords:  
migraine, depression, GWAS, meta-analysis, genetic correlation, shared genetics. 
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INTRODUCTION 
Migraine and major depressive disorder (MDD) are among the most common 
neurological disorders, each affecting approximately 10–20% of the population with 
more females than males affected.1-3 Bidirectional comorbidity between migraine and 
MDD is widely recognised;4-8 it highly reduces the quality of life of patients with a huge 
impact on relatives and society.9 As epidemiological studies have revealed a moderate 
heritability for migraine and MDD with estimates ranging from 30–50%,10,11 shared 
genetic factors may underlie these disorders,12-14 although molecular evidence for such an 
association is lacking. 
A number of genome-wide association studies (GWAS) have been conducted 
separately for migraine15-21 and MDD22-33. For both disorders an increasing number of 
loci have been identified. The largest, latest, migraine GWAS analysed 59,674 cases and 
316,078 healthy controls and identified 38 genome-wide significant (PSNP ≤ 5 × 10-8) loci 
containing 44 independent single nucleotide polymorphisms (SNPs) associated with 
migraine risk.21 While the largest, latest, MDD GWAS analysed a combined 130,620 self-
reported and clinically evaluated lifetime major depression cases and 347,620 controls 
identified 15 genome-wide significant loci, containing 17 independent SNPs associated 
with MDD risk.33 Comparison of the genome-wide significant loci between the two 
disorders yielded no shared loci. It remains however of interest to investigate whether 
signals of other SNPs, below the threshold for genome-wide significance, reveal 
molecular genetic overlap between migraine and MDD.  
Compared to epidemiological studies, analysing GWAS SNP data provides an 
opportunity to test for genetic overlap between migraine and MDD at the molecular 
genetic level and can yield genetic risk variants associated with both migraine and MDD. 
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Also, extending the genetic overlap analysis from the SNP-level to the gene-level—given 
that genes are the predominant functional unit of the human genome and more closely 
related to biology than individual SNPs—can (i) provide novel evidence on the genetic 
association between migraine and MDD; (ii) give insight into shared biological pathways 
underlying the two disorders; and (iii) help identify target genes for drug development. 
Moreover, the identification of genetic overlap and specific genetic variants shared across 
disorders can be used to assess the validity of the clinical diagnosis and classification of 
patients. 
Here we examined the genetic overlap across migraine and MDD by (i) evaluating 
SNP-based genetic overlap utilising LD (linkage disequilibrium) Score regression (LDSC) 
and SNP effect concordance analysis (SECA) using genome-wide summary statistics 
from the 2016 International Headache Genetics Consortium (IHGC) migraine and 2013 
Psychiatric Genomics Consortium (PGC) MDD GWAS, and the ‘top’ 10,000 most 
significant SNP results from the 2016 23andMe MDD GWAS; (ii) identifying genetic 
risk variants associated with both migraine and MDD by meta-analysis of 2016 IHGC 
migraine and 2016 23andMe MDD GWAS results; (iii) evaluating gene-level genetic 
overlap across migraine and MDD to identify genes associated with migraine and MDD 
using gene-based association analysis of summary statistics from the 2016 IHGC 
migraine and 2013 PGC MDD GWAS; and (iv) exploring the biological pathways 
represented by the genes showing association to migraine and MDD. 
 
MATERIALS AND METHODS 
Study samples 
2016 IHGC migraine GWAS 
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The 2016 IHGC (http://www.headachegenetics.org/) migraine GWAS sample is 
comprised of 59,674 migraine cases and 316,078 healthy controls;21 all participants were 
of European ancestry. Migraine phenotypes were diagnosed by self-reported 
questionnaires or clinical interviews according to the International Classification of 
Headache Disorders (ICHD) criteria.34 Subjects in each individual GWAS had their 
specific standard genotyping platform and quality control criteria, which were 
summarised elsewhere;21 all subjects were imputed using the 1000 Genomes Project35 
reference panel (Phase I, v3 release or later). Each individual GWAS also performed their 
association analysis independently, adjusted for sex and the top ten principal components 
to account for potential population stratification where required.21 A combined fixed-
effect (FE) meta-analysis was then performed using the Genome-wide Association Meta-
Analysis (GWAMA) program.36 After SNP filtering, the final 2016 IHGC migraine 
GWAS included association results for 8,045,569 SNPs. For more detailed descriptions 
of the migraine cohorts and statistical analyses, please refer to the original publication.21 
Here, we utilised the GWAMA output after excluding results from the 23andMe GWAS 
sample (30,465 migraine cases and 143,147 controls), leaving a total migraine GWAS 
sample of 29,209 cases and 172,931 controls, to ensure there was no sample overlap 
between 2016 IHGC migraine GWAS and the 2016 23andMe MDD GWAS. 
 
2013 PGC MDD GWAS 
The 2013 PGC (http://pgc.unc.edu) MDD GWAS sample comprised 18,759 unrelated 
participants of European ancestry (9,240 MDD cases and 9,519 healthy controls) from 
nine MDD GWA case-control samples.23 All MDD cases were diagnosed by a structured 
clinical interview or clinical-based checklist according to the Diagnostic and Statistical 
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Manual of Mental Disorders, fourth edition (DSM-IV) criteria.37 The PGC performed a 
mega-analysis, which required centralising the genotype data from all GWA samples 
prior to performing consistent QC, imputation and association analysis. Individual 
genotypes were all imputed up to the CEU (Utah Residents with Northern and Western 
European Ancestry) and TSI (Toscani in Italy) HapMap3 reference panel. Association 
analysis was carried out using a logistic regression assuming an additive SNP effect 
(allelic association) model. The final 2013 PGC MDD GWAS comprised results for 
1,232,794 SNPs. 
 
2016 23andMe MDD GWAS 
The 2016 23andMe MDD discovery GWAS sample33 recruited 307,354 subjects of 
European ancestry, including 75,607 self-reported MDD cases and 231,747 healthy 
controls. Subjects were systematically genotyped, QCd, and imputed using the 1000 
Genomes Project35 Phase I reference panel. Under the assumption of additive allelic 
effects, GWA analysis was performed using logistic regression adjusted for age, sex, and 
the top five ancestry principal components. After removing SNPs with low quality 
imputation, 13,519,496 SNPs were included in the discovery GWAS; and only the top 
10,000 most significant SNPs 
(http://www.nature.com/ng/journal/v48/n9/full/ng.3623.html#supplementary-
information) with P ≤ 1 × 10-5 were available for download and used in our study.  
In addition to the above details and original publications describing the GWAS 
summary statistics analysed in our study―including URLs from where the data can be 
obtained online―details and data from the analysed datasets are available from the 
GWAS Central database (http://www.gwascentral.org/study/HGVST1855). 
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Genetic analyses 
LD Score regression to evaluate genetic similarity 
LD Scores were calculated according to the European 1000 Genomes Project haplotype 
reference data (Phase I, v3). LD Score regression was performed using the LDSC 
software (https://github.com/bulik/ldsc).38 GWAS summary statistics from the 2016 
IHGC migraine GWAS and the 2013 PGC MDD GWAS were utilised in this analysis. 
GWAS data were reformatted and harmonised utilising the “munge_sumstats.py” script, 
based on the SNP list used in LD score calculation. As per the LDSC manual, SNPs were 
removed if they were not present in the relevant reference data, had a rare frequency 
(minor allele frequency [MAF] ≤ 0.01), were poorly imputed (INFO score ≤ 0.90) or 
strand-ambiguous. We first performed single-trait LD Score regression to evaluate the 
SNP-based liability heritability (h2SNP) for the 2016 IHGC migraine and 2013 PGC MDD 
GWAS, using their sample prevalence of 14.5% for migraine and 49.3% for MDD, and a 
population prevalence of 15% for both migraine and MDD; and then built a cross-trait 
LD Score regression to estimate the genetic correlation (rG) between migraine and MDD. 
 
SECA analysis to evaluate genetic overlap 
Whereas LD Score regression requires GWAS results for millions of SNPs spread evenly 
across the genome, SECA is able to assess genetic overlap for a subset of SNPs.39 Since 
only the top 10,000 most significant SNPs (P value ≤ 1 × 10-5) were available for the 
2016 23andMe MDD GWAS, we utilised SECA to examine the genetic overlap between 
the 2016 IHGC migraine GWAS and 2016 23andMe MDD GWAS. SECA first aligned 
the SNP effects across the two GWA study summary results to the same effect allele, and 
then extracted a subset of independent SNPs via ‘P value informed’ linkage 
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disequilibrium (LD) clumping. The approach iterated from the first to last SNP on each 
chromosome sorted from smallest to largest 2016 IHGC migraine GWAS P value that 
had not already been clumped (denoting this as the ‘index’ SNP) and formed clumps of 
all other SNPs that are within 1 Mb and in LD (r2 > 0.1, based on 1000G PhaseI v3 CEU 
genotype data) with the index SNP. A second round of LD clumping was performed to 
clump any of the round 1 index SNPs within 10 Mb of each other to account for long-
range LD (r2 > 0.1). The approach identified the subset of independent (index) SNPs with 
the most significant association P values in the 2016 IHGC migraine GWAS. After 
subgrouping SNPs with P value thresholds P ≤ {0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 
0.8, 0.9, 1.0} in the 2016 IHGC migraine GWAS, two-sided exact binomial tests were 
performed to assess the concordance of SNP effect directions across the 2016 IHGC 
migraine GWAS and 2016 23andMe MDD GWAS results. 
 
Meta-analysis of migraine and MDD 
Meta-analysis of the 2016 IHGC migraine GWAS and 2016 23andMe MDD GWAS (for 
the top 10,000 SNPs) was performed using the METASOFT (URL: 
http://genetics.cs.ucla.edu/meta/) inverse variance‒weighted FE model,40 where the SNP 
effect size estimates (β) are weighted by their estimated standard errors (se) to calculate 
a meta-analysis P value. To allow for the presence of effect heterogeneity across studies, 
the METASOFT Han and Eskin’s random-effects (RE2) model40 was also utilised, as it  
is optimized to detect associations under heterogeneity. A total of 8,687 SNPs in both the 
2016 IHGC migraine and 2016 23andMe MDD GWAS were included in the meta-
analysis. Following the meta-analysis, we calculated the LD (r2) between the implicated 
SNPs (PSNP ≤ 5 × 10-8) at each locus using PLINK 
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(http://pngu.mgh.harvard.edu/purcell/plink/)41 and the European 1000 Genomes Project 
haplotype reference data (Phase I, v3).  
 
Gene-based analysis to evaluate genetic overlap 
A gene-based approach42 was also used to evaluate the genetic overlap across the 2016 
IHGC migraine GWAS and 2013 PGC MDD GWAS. After downloading RefSeq gene 
information (hg19) from the UCSC genome browser (accessed 20 March 2014), 
overlapping isoforms of the same gene were combined to form a single full-length version 
of the gene, while isoforms that did not overlap were left as duplicates of that gene. This 
led to 23,438 unique genes. The common SNPs from the 2016 IHGC migraine and 2013 
PGC MDD GWAS were then assigned to genes if they mapped to between 15 kb 5’ of 
the transcription start site (TSS) and 15 kb 3’ of the transcription end site (TES). This 15-
kb gene boundary extension was chosen based on the observation that 90% of SNPs 
effecting expression quantitative trait loci (eQTLs) are within this proximity.43 Gene-
based association tests were performed using the GATES test44 implemented in the Fast 
ASsociation Tests (FAST) package.45 GATES performs gene-based tests by adjusting the 
observed P value of the most significant SNP assigned to a gene by the total effective 
number of independent SNPs tested across the gene. GATES performs eigenvalue 
analysis of the n×n SNP correlation matrix (estimated from the 1000 Genomes Project 
[released on May 2012] CEU reference population) for each gene to estimate the effective 
number of independent SNPs. The original report introducing the GATES gene-based test 
used computer simulation to demonstrate that the test offers effective control of the type 
1 error rate regardless of gene size and LD pattern among SNPs, and does not need 
permutation or simulation to validate significance.44 
 13 
 
Given that gene-based association results may be correlated across neighbouring 
genes due to LD between the most significant SNP assigned to each gene, we estimated 
the effective number of independent genes (i.e., number of independent gene-based tests) 
by examining the LD between the top (most) significant SNP assigned to each gene. This 
calculation was performed using the Genetic type I Error Calculator (GEC).46 The GEC 
approach first divides the input SNPs into LD blocks, and assumes LD blocks are 
independent by ensuring the SNPs between blocks are not in LD (r2 < 0.1). GEC 
subsequently performs eigenvalue analysis of the correlation matrix for each LD block to 
estimate the effective number of independent SNPs. In the original report introducing the 
GEC,46 computer simulation and permutation was used to demonstrate that using the GEC 
estimate of the effective number of independent SNPs in a Bonferroni procedure yields 
correct type I error rates and behaves similarly to the gold standard of permutation. 
To test genetic overlap, we first generated gene sets for each disorder based on three 
levels of significance (i.e., gene-based P value ≤ 0.01, 0.05, or 0.1) to allow for 
differences in power across the different GWA studies, and then calculated the effective 
number of independent genes per disorder. Next, we set the 2016 IHGC migraine GWAS 
as the ‘discovery’ dataset and 2013 PGC MDD GWAS as the ‘target’ dataset to test for 
genetic overlap according to three P value significance levels (e.g., test whether the 
proportion of genes with a gene-based P value ≤ 0.05 for both migraine and MDD was 
more than expected by chance). The observed number of overlapping genes was defined 
as the effective number of genes with P values less than the threshold in both the 
discovery and target datasets. The observed proportion of overlapping genes was the 
observed effective number of overlapping genes divided by the effective number of genes 
with a P value less than the threshold in the discovery dataset. The expected proportion 
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of overlapping genes was the effective number of genes with a P value less than the 
threshold in the target dataset divided by the total effective number of genes in the target 
dataset. The statistical significance of whether the number of overlapping genes was more 
than expected by chance was calculated using one-sided exact binomial tests. Moreover, 
to identify the individual genes associated across migraine and MDD, we combined gene-
based evidence for association across the two disorders using the Fisher’s combined P 
value approach. This gene-based approach was recently utilised to show gene-based 
pleiotropy across migraine with aura and migraine without aura,42 as well as the five 
major disorders in the PGC: attention deficit hyperactivity disorder, autism spectrum 
disorder, bipolar disorder, MDD, and schizophrenia.47 
 
Pathway analysis of overlapping genes 
To discover shared biological pathways underlying migraine and MDD, we performed a 
pathway analysis of the significant overlapping genes from the gene-based analysis using 
the g:GOSt tool of the g:Profiler web server (http://biit.cs.ut.ee/gprofiler/).48 The 
overlapping genes with Fisher’s combined P value lower than 1 × 10-3 were selected49 
and evaluated using the g:Profiler web server. The g:GOSt tool can identify significantly 
enriched pathways through different functional databases including Gene Ontology 
(GO)50 (biological process, cellular component and molecular function), Kyoto 
Encyclopedia of Genes and Genomes (KEGG),51 and Reactome.52 Further advanced 
options are also available for term filtering, including the functional category size 
thresholds for limiting enrichment analyses and the significance threshold for multiple 
testing (e.g., Benjamini-Hochberg False Discovery Rate [FDR], and Bonferroni 
correction). For our analyses, no size boundaries were set for functional category and 
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term intersection; Benjamini-Hochberg FDR was utilised for multiple testing correction; 
and other advanced options were kept as their default. Analyses were first run without 
including then run including electronic GO annotations. Lastly, given such pathway 
analyses may be biased in the presence of strong LD across neighbouring genes, we 
ensured the enriched pathways did not contain genes with top significant SNPs in LD (r2 > 
0.1). 
 
RESULTS 
LD Score-based genetic correlation between migraine and MDD 
As summarised in Table 1, using LD Score regression with no intercept constraining, we 
observed a significant SNP-based liability-scale heritability of 12% (95% CI: 9–15%) for 
2016 IHGC migraine, and 19% (95% CI: 12–26%) for 2013 PGC MDD. For cross-trait 
analysis, a significant positive genetic correlation (rG) of 0.25 (95% CI: 0.01–0.48) was 
estimated between the 2016 IHGC migraine and 2013 PGC MDD GWAS.  
 
SECA-based genetic concordance between migraine and MDD 
SECA revealed a significant genetic concordance between genetic risk factors (SNP risk 
alleles) for 2016 IHGC migraine and 2016 23andMe MDD. For instance, the SNP effect 
concordance between migraine and MDD is considerable given that of the 358 
independent SNPs with the smallest P values in the 2016 IHGC migraine GWAS, the risk 
increasing allele for MDD and migraine was the same for 202 (56.42%, two-sided 
binomial test P = 0.017). The SNP effect concordance was further enriched (by 31%) in 
the subset of independent SNPs with nominal MDD association (P ≤ 0.05), with 34 
(73.91%) out of 46 independent SNPs having the same risk increasing allele for migraine 
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and MDD (two-sided binomial test P = 0.0016). SNP effect concordance results for all 
12 analysed P value thresholds are provided in Table 2. 
 
Genetic risk variants associated with both migraine and MDD 
A total of 683,106 participants were included in the meta-analysis of 2016 IHGC migraine 
and 2016 23andMe MDD GWAS. In total, 542 SNPs at 9 genomic loci produced evidence 
for genome-wide significant association (PSNP ≤ 5 × 10-8) based on the FE model 
(Supplementary Table 1 contains meta-analysis results for the 542 SNPs using both the 
FE and RE2 model). After examining LD between the most significant (‘top’), or ‘index’, 
risk SNPs, 9 independent SNPs were identified (Table 3). 
Among these 9 independent SNPs, 5 of them (rs12127789 
hg19.chr1:g.72740073G>T, rs2195636 hg19.chr3:g.158352440C>T, rs768705 
hg19.chr5:g.87568710A>G, rs9536359 hg19.chr13:g.53691446C>T and rs5751069 
hg19.chr22:g.41627775C>G) presented a significantly stronger association with MDD 
(either the SNP showed a genome-wide significant association or the SNP was in LD with 
a genome-wide significant SNP) compared to migraine, indicating that these SNPs are 
predominantly driven by the association signal in the 2016 23andMe MDD GWAS. 
However, one SNP (rs6476606 hg19.chr9:g.37005561A>G) showed near suggestive 
association (PSNP ≤ 1 × 10-5) with both MDD (PSNP = 1.5 × 10-5) and migraine (PSNP = 4 
× 10-4), and was genome-wide significantly associated with MDD (PSNP = 1.2 × 10
-8) in 
the published joint analysis of 23andMe discovery, PGC, and 23andMe replication MDD 
GWAS.33 Thus providing an ideal example where combining MDD GWAS and migraine 
GWAS results can improve power to identify risk loci for MDD. The remaining 3 SNPs 
(rs146377178 hg19.chr8:g.25386973C>T, rs672931 hg19.chr11:g.30920897T>C, and 
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rs11858956 hg19.chr15:g.70261228T>C) showed suggestive association with MDD (and 
are not in LD [r2 < 0.1] with genome-wide significant SNPs) also showed association 
with migraine (PSNP ≤ 0.005), and are novel genome-wide significant risk loci. SNP 
rs146377178 is located between CDCA2 and EBF2 on chromosome 8p21.2, rs672931 is 
located within DCDC5 on 11p14.1, and rs11858956 is located between RPLP1 and TLE3 
on 15q23. 
 
Gene-based genetic overlap between migraine and MDD 
As summarised in Table 4, similar to the SNP-based analysis, a significant gene-level 
genetic overlap between migraine and MDD was observed. For instance, a significant 
proportion of genes with gene-based P value ≤ 0.05 overlapped between migraine and 
MDD (Pbinomial-test = 0.001): the observed proportion (8.7%) of genes with a gene-based P 
value ≤ 0.05 in both migraine and MDD is significantly higher than the expected 
proportion (6.5%) of genes with P value ≤ 0.05 for MDD. Furthermore, the use of a less 
stringent gene-based P value threshold ≤ 0.1 produced more significant genetic overlap 
across two disorders (Pbinomial-test = 2.60 × 10
-6), while the use of a more stringent gene-
based P value threshold ≤ 0.01 produced fewer significant genetic overlap (Pbinomial-test = 
0.045). 
Combining gene-based evidence for association across the disorders (2016 IHGC 
migraine and 2013 PGC MDD) using Fisher’s combined test (Table 5), two genes were 
identified with combined P values that are below the genome-wide significance threshold 
adjusted for 13,524 independent gene-based tests (3.7 × 10-6 = 0.05/13,524), namely 
ANKDD1B on chromosome 5q13.3 and KCNK5 on 6p21.1. Interestingly, the effect 
alleles of the top SNPs driving the ANKDD1B gene-based association (rs34358 
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hg19.chr5:g.74965122G>A for migraine and rs904743 hg19.chr5:g.74917862A>G for 
MDD) and the KCNK5 association (rs9394578 hg19.chr6:g.39165859C>A for migraine 
and rs2815095 hg19.chr6:g.39156108T>C for MDD) had opposite effects on risk for 
migraine and MDD, and were in weak LD (r2 = 0.24 and 0.39, respectively), providing 
evidence for allelic heterogeneity at these associated genes. 
 
Pathway analysis of the overlapping genes 
Pathway analysis was performed for a total of 86 overlapping genes with PFisher’s-combined 
≤ 1 × 10-3 (see Supplementary Table 2). After excluding pathways having common genes 
with top significant SNPs in LD r2 > 0.1, 39 pathways with 21 genes were enriched (FDR 
≤ 0.05) with at least one annotation of a human gene (summarised in Table 6), from which 
10 pathways with 12 genes showed at least two human gene annotations. 
Among these pathway terms, neural-related pathways were substantially over-
represented, especially for pathways related to signalling (e.g., “Wnt signalling pathway”; 
KEGG:04310; PLCB3, SERPINF1 and DVL3; FDR P value = 0.02) and the ion channel 
regulations (e.g., “potassium ion leak channel activity”; GO:0022841; KCNK5 and 
KCNK4; FDR P value = 0.02), both of which were also strongly dominant in the pathways 
with at least two human gene annotations. Enzymatic activity-related pathways (e.g., 
“serine O-acyltransferase activity”; GO:0016412; MBOAT4; FDR P value = 0.05) and 
metabolic pathways (e.g., “arsonoacetate metabolic process”; GO:0018872; AS3MT; 
FDR P value = 0.05) were also observed to be enriched in migraine and/or MDD etiology. 
Notably, only one term “endocrine and other factor-regulated calcium reabsorption” 
(KEGG:04961; PLCB3 and AP2M1; Bonferroni corrected P value = 0.05) remained after 
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using more conservative Bonferroni correction for multiple testing, which is related to 
processes of intracellular signalling and neuronal excitability.53 
Extending pathway analyses to also include functional annotations of GO assigned 
by in silico curation methods (Inferred from Electronic Annotation [IEA]) provided 
further evidence for the molecular signalling-related pathways involved in migraine 
and/or MDD etiology, with 38 additional pathways (see Supplementary Table 3) 
represented by 11 genes (ECM1, DLST, TMEM208, PLXNB1, RNF113B, FARP1, 
CLEC17A, GPR126, CENPH, GRK6, and TFB1M). Importantly, this analysis highlighted 
seven pathways with at least two human gene annotations: “regulation of release of 
cytochrome c from mitochondria” (GO:0090199; NOL3 and BAD; FDR P value = 0.03); 
“negative regulation of peptidase activity” (GO:0010466; NOL3, ECM1, NGF and 
SERPINF1; FDR P value = 0.03); “negative regulation of cytokine-mediated signaling 
pathway” (GO:0001960; NOL3 and ECM1; FDR P value = 0.03); “Rac GTPase binding” 
(GO:0048365; DVL3 and FARP1; FDR P value = 0.03); “cysteine-type endopeptidase 
regulator activity involved in apoptotic process” (GO:0043028; NOL3 and BAD; FDR P 
value = 0.03); “extracellular matrix binding” (GO:0050840; ECM1 and GPR126; FDR P 
value = 0.05); and “death receptor binding” (GO:0005123, NOL3 and NGF; FDR P value 
= 0.05). 
 
DISCUSSION 
Here we performed a comprehensive analysis to assess the genetic overlap between 
migraine and MDD using three GWAS data sets, which is the first systematic study aimed 
at identifying shared genetic factors between migraine and MDD at the molecular genetic 
level. Several interesting findings are noteworthy. 
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Firstly, we estimated a significant SNP-based liability-scale heritability of 12% using 
the 2016 IHGC migraine GWAS data set and 19% using the 2013 PGC MDD GWAS 
data set. The SNP-based heritability estimates of migraine and MDD are lower than those 
estimated from twin and family studies.10,11 This so-called “missing heritability” is likely 
due to the combined effects of rare SNPs and SNPs with small effects that are difficult to 
capture using current GWAS sample sizes and analysis of common SNPs.54,55  
Our study reported a significant SNP-based rG of 0.25 between migraine (2016 IHGC) 
and MDD (2013 PGC), which is similar to estimates (rG = 0.30–0.36) from twin and 
family studies.13,14 Although the rG between 2016 IHGC migraine and 2016 23andMe 
MDD could not be assessed via LD Score regression (due to the restricted availability of 
genome-wide results for the 23andMe MDD GWAS), our SECA results provided strong 
evidence for a significant genetic overlap, indicated by the significant enrichment in 
concordant SNP effects across the 2016 IHGC migraine and 2016 23andMe MDD GWAS. 
Given the strong evidence for shared genetic factors, we performed a meta-analysis 
of the 2016 IHGC migraine and 2016 23andMe MDD GWA studies. No substantial 
difference was observed when comparing results of the FE and the RE2 models 
(Supplementary Table 1), indicating negligible SNP effect heterogeneity across studies. 
The meta-analysis identified 3 novel (index) SNP loci near several genes: rs146377178 
between CDCA2 and EBF2, rs672931 within DCDC5, and rs11858956 between RPLP1 
and TLE3. Whereas little evidence exists that supports a biological role in migraine or 
MDD risk for DCDC5 and TLE3, at least some evidence is reported in the literature for 
the other three genes. Specifically, CDCA2, which is related to cell division cycle, was 
previously observed to be involved in the overlapping pathways across migraine with 
aura and migraine without aura;42 EBF2 is reported to play a role in regulating 
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dopaminergic neurons in the midbrain periaqueductal grey matter, which is relevant to 
pain modulation,56 and therefore may contribute to both migraine and MDD risk; and 
RPLP1 was revealed to be related to MDD in a mouse model, suggesting that the 
ribosome pathways of proteins synthesis/degradation were implicated in MDD etiology.57  
One SNP (rs6476606) showed association in both the 2016 IHGC migraine GWAS 
(PSNP = 0.0003) and 2016 23andMe MDD discovery GWAS (PSNP = 1.50 × 10
-5), with 
genome-wide significant evidence for association in the FE meta-analysis (PSNP = 2.52 × 
10-8), and genome-wide significant association with MDD in the joint analysis of 
23andMe discovery, PGC, and 23andMe replication MDD GWAS (PSNP = 1.2 × 10
-8).33 
This indicates that combining migraine and MDD GWAS data has the potential to identify 
robust MDD risk loci. Interestingly, this finding is in line with previous results suggesting 
that in at least a subset of migraine patients with MDD, migraine may be a symptom or 
consequence of MDD.58 Further research will be required to determine whether 
combining migraine and MDD GWAS data can help to identify robust migraine risk loci 
(e.g., utilising genome-wide results from more powerful MDD GWAS). 
Extending our analysis from SNP-level to gene-level revealed a significant genetic 
overlap across migraine and MDD, providing additional evidence for such overlap 
(‘pleiotropy’) between the disorders. Application of Fisher’s combined test identified two 
genes with genome-wide significant gene-based P values (ANKDD1B and KCNK5). 
Although minimal data exists for ANKDD1B, it may be relevant to migraine and MDD 
susceptibility due to its role in coding ankyrin-repeat proteins, which have been 
associated with a number of human disorders, and include the Notch protein (a key 
component of cell signalling pathways) in which mutations can cause cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
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(CADASIL)―for which the most common clinical manifestations are migraine 
headaches and transient ischemic attacks.59 In contrast, the two-pore forming potassium 
channel gene KCNK5 is an attractive candidate for disorders of the central nervous system 
and other members of this protein family have already been linked to migraine or MDD 
susceptibility. For instance, although the genetic evidence has been debated,60,61 the 
TWIK-related spinal cord potassium channel (TRESK, encoded by KCNK18) has been 
associated with migraine susceptibility;62,63 and the inactivation of the TWIK-related 
potassium channel (TREK, encoded by KCNK4) produces a depression-resistant 
phenotype in a mouse model.64 
Based on the significant overlapping genes identified in gene-based association 
analyses, multiple pathways were observed, which were over-presented in neural-related 
pathways such as metal ion channel regulations, signalling pathways, and enzymatic 
activity. These results provide evidence for the importance of neurological mechanisms 
on triggering comorbid migraine and MDD, suggesting that comorbid migraine and MDD 
may be induced by their shared neurological symptoms. 
Our study has limitations. Firstly, LD Score regression defaults with calculating 
heritability based on the observed scale. Although we converted the conditions onto the 
liability scale by setting a fixed population and sample prevalence of migraine and MDD, 
the estimates may still be underestimated due to the relatively high sample prevalence of 
PGC MDD (around 50%). In addition, we identified a very small genetic covariance 
intercept of 0.04, indicating a small sample overlap between 2016 IHGC migraine GWAS 
and 2013 PGC MDD GWAS that may have influenced our gene-based association 
analyses. However, we believe such effects will be negligible since the intercept is very 
close to zero. Moreover, the restricted availability of genome-wide GWAS summary 
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statistics for the 2016 23andMe MDD GWAS limited our findings: (1) we could not 
estimate a genetic correlation between the 2016 IHGC migraine and 2016 23andMe MDD 
GWAS using LD Score regression; hence, we utilised SECA to test for their genetic 
overlap; (2) it is possible most of the genome-wide significant SNPs from meta-analysis 
of migraine and MDD showed a stronger signal for MDD compared to migraine because 
the 2016 23andMe MDD GWAS was limited to the top 10,000 SNPs (i.e., ‘weaker’ MDD 
SNP associations were not meta-analysed); and (3) we could not perform a complete 
genome-wide meta-analysis of the 2016 IHGS migraine and 2016 23andMe MDD 
GWAS; nor could we perform gene-based genetic overlap analysis across the 2016 IHGC 
migraine and 2016 23andMe MDD GWAS. Lastly, because our gene-based association 
tests assigned SNPs to genes based on close proximity (i.e., within 15 kb 5’ of the TSS 
site and 15 kb 3’ of the TES), more distant SNPs associated with gene-to-phenotype risk 
may influence the interpretation of our gene-based overlap analyses.  
In conclusion, we have shown a significant genetic overlap across migraine and 
MDD at both the SNP- and gene-level. Importantly, we identified three novel independent 
genome-wide significant SNPs (rs146377178, rs672931, and rs11858956; located 
between CDCA2 and EBF2, within DCDC5, and between RPLP1 and TLE3, respectively), 
and two genome-wide significant genes (ANKDD1B and KCNK5). Multiple pathway 
terms, especially the neural-related pathways of signalling and metal ion channel 
regulation, were implicated. Overall, our study provides strong molecular genetic support 
for shared genetically controlled mechanisms underlying migraine and MDD risk, and 
provide impetus to perform further combined analyses of migraine and MDD GWAS data.  
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